Medical/Pharmaceuticals News & Press Release Distribution

OnCusp Therapeutics Receives FDA Clearance for the Phase 1 Clinical Trial of CUSP06, Targeting Ovarian Cancer and Other Advanced Solid Tumors

NEW YORK, Aug. 15, 2023 /PRNewswire/ -- OnCusp Therapeutics, a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, announced today the clearance of its Investigational New Drug (IND) Applicatio...

2023-08-15 20:00 1049

Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System

SHANGHAI, Aug. 15, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Government of Hong Kong Specia...

2023-08-15 16:52 1721

Leading Asia Pacific Biopharmas Power Digital Engagement with Veeva CRM

Eighteen of the top 20 biopharmas standardize with Veeva to build meaningful customer relationships SINGAPORE, Aug. 15, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 18 of the top 20 biopharmas inAsia Pacific are using Veeva CRM

2023-08-15 09:00 2480

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Non-profit drug developer partners with leading manufacturer of medicine in Pakistan NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medici...

2023-08-14 21:30 1670

Orthopedic brace can help reduce pain from Hallux Valgus - The Footing Health K releases Toe braces!

* Launch of an instrument to correct bunions SEOUL, South Korea, Aug. 14, 2023 /PRNewswire/ -- When the toes are corrected, our entire body shape, starting from the toes, is corrected. The process of correction starting from the toe can be seen as a process of correcting the connection between ...

2023-08-14 20:00 1110

UMP Introduces Artificial Intelligence Technology for Enhanced Chest X-Ray Analysis Efficiency

HONG KONG, Aug. 14, 2023 /PRNewswire/ -- UMP Healthcare Holdings Limited ("UMP " or the "Group", stock code: 722.HK) is pleased to announce the signing of a memorandum of understanding (MOU) withImsight Technology Company Limited, specialised in providing artificial intelligence (AI) medical imag...

2023-08-14 15:45 1912

UMP Introduces Artificial Intelligence Technology for Enhanced Chest X-Ray Analysis Efficiency

Kelun-Biotech announces that a Phase III clinical trial of core product SKB264 (MK-2870, TROP2-ADC) in patients with unresectable locally advanced, recurrent or metastatic TNBC who have failed second-line or above prior standard of care has met its primary endpoint

CHENGDU, China, Aug. 14, 2023 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. ("Kelun-Biotech", HKEX: 6990.HK) announced today that its innovative TROP2-ADC (SKB264, also known as MK-2870) met the primary endpoint in the randomized, controlled, open-label, multi-center Phase III ...

2023-08-14 12:50 3104

Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach

PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a$1M contract spanning two years (HHSF223018186...

2023-08-11 21:14 3040

Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer

SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical tr...

2023-08-11 17:00 3768

Move Aside Anti-Ageing, It's Age Reversal We're Talking Now

SINGAPORE, Aug. 11, 2023 /PRNewswire/ -- In the realm of medical progress, the horizon extends far beyond the battle against diseases. Now, the concept of "age reversal" — not merely slowing down or halting ageing — stands as a tangible reality. However, the validity and accuracy of ageing measur...

2023-08-11 13:49 1820

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...

2023-08-11 11:14 1738

WuXi XDC and Boostimmune Sign MOU for Integrated Services

SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating ...

2023-08-11 08:30 1312

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies modulating the tumor immune micr...

2023-08-11 08:30 4097

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China

- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and improving access of the drug to patients in the mainland ofChina - Antengene to receive up to RMB200 million in upfront payments,...

2023-08-11 08:00 2537

First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Aug. 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed inChina in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the i...

2023-08-11 07:18 1775

YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023

GAITHERSBURG, Md., Aug. 10, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2023-08-11 04:30 4593

Datasea Launches Innovative "Intelligent Acoustics" Subsidiary in Delaware, Unveiling AI-Integrated Offerings for US Market

BEIJING, Aug. 10, 2023 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology corporation engaged in three converging and innovative business segments inChina: intelligent acoustics, 5G messaging, and smart city technology, announced the inception of a who...

2023-08-10 21:30 3359

HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics

CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research service agreement with Nested Therapeutics, Inc. ("Nested"), a biotechnology company pioneering a next-generation precisi...

2023-08-10 21:30 1695

Standigm and Nashville Biosciences join to revolutionize early drug discovery

Companies will identify novel therapeutic targets using Standigm's explainable AI and Nashville Biosciences' datasets SEOUL, South Korea, Aug. 10, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discovery and develop...

2023-08-10 21:07 1266

Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact

SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. ("Oricell") has received the green light for its Investigational New Drug (IND) application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed...

2023-08-10 21:00 2015